See more : Guangdong Songfa Ceramics Co.,Ltd. (603268.SS) Income Statement Analysis – Financial Results
Complete financial analysis of Zomedica Corp. (ZOM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Zomedica Corp., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Zhejiang Starry Pharmaceutical Co.,Ltd. (603520.SS) Income Statement Analysis – Financial Results
- GrandVision N.V. (GVNV.AS) Income Statement Analysis – Financial Results
- Chimera Energy Corporation (CHMR) Income Statement Analysis – Financial Results
- Zhejiang China Commodities City Group Co., Ltd. (600415.SS) Income Statement Analysis – Financial Results
- Luxbright AB (publ) (LXB.ST) Income Statement Analysis – Financial Results
Zomedica Corp. (ZOM)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.zomedica.com
About Zomedica Corp.
Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company engages in the development and commercialization of TRUFORMA platform, which offers point-of-care diagnostic products for disease states in dogs and cats; and PulseVet, provides for treatment of various musculoskeletal issues, such as broken bones, tendonitis, and torn ligaments in horses and small animals. It has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for development and markets a novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 25.19M | 18.93M | 4.13M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 7.87M | 5.28M | 1.08M | 530.02K | 787.61K | 205.77K | 92.41K | 45.82K | 0.00 | 0.00 | 0.00 |
| Gross Profit | 17.32M | 13.65M | 3.05M | -530.02K | -787.61K | -205.77K | -92.41K | -45.82K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 68.76% | 72.12% | 73.89% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 5.74M | 2.58M | 1.67M | 8.04M | 10.35M | 10.32M | 2.75M | 1.52M | 758.05K | 0.00 | 0.00 |
| General & Administrative | 29.03M | 22.93M | 0.00 | 7.93M | 8.18M | 5.83M | 5.08M | 4.24M | 1.43M | 42.41K | 77.50K |
| Selling & Marketing | 14.14M | 9.88M | 0.00 | 261.91K | 471.89K | 225.89K | 164.25K | 194.19K | 143.47K | 0.00 | 0.00 |
| SG&A | 43.17M | 33.00M | 22.75M | 8.19M | 8.65M | 6.06M | 5.24M | 4.43M | 1.57M | 42.41K | 77.50K |
| Other Expenses | 0.00 | -7.00K | 6.00K | 530.02K | 787.61K | 205.77K | 92.41K | 45.82K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 48.91M | 35.58M | 24.43M | 16.76M | 19.78M | 16.58M | 8.08M | 6.00M | 2.28M | 42.41K | 77.50K |
| Cost & Expenses | 56.78M | 40.85M | 25.51M | 16.76M | 19.78M | 16.58M | 8.08M | 6.00M | 2.28M | 42.41K | 77.50K |
| Interest Income | 5.46M | 2.70M | 357.45K | 32.86K | 18.34K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 175.00K | 1.00K | 6.05K | 732.00 | 18.34K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 6.30M | 4.04M | 1.14M | 530.02K | 787.61K | 205.77K | 92.41K | 45.82K | 9.05K | 0.00 | 0.00 |
| EBITDA | -29.39M | -15.34M | -19.57M | -16.38M | -19.00M | -16.44M | -7.97M | -5.97M | -2.28M | -42.41K | -77.50K |
| EBITDA Ratio | -116.68% | -80.23% | -479.66% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -31.59M | -21.92M | -21.37M | -16.76M | -19.78M | -16.58M | -8.08M | -6.00M | -2.29M | -42.41K | -77.50K |
| Operating Income Ratio | -125.43% | -115.81% | -517.14% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -4.27M | 2.54M | 657.78K | -146.81K | 273.00 | -68.44K | 18.98K | 258.06K | 7.44K | 0.00 | 0.00 |
| Income Before Tax | -35.86M | -19.38M | -20.72M | -16.91M | -19.78M | -16.65M | -8.07M | -6.01M | -2.28M | -42.41K | -77.50K |
| Income Before Tax Ratio | -142.38% | -102.38% | -501.22% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -1.33M | -2.37M | -2.33M | 9.33K | 38.08K | 136.88K | -18.98K | 28.59K | 0.00 | 0.00 | 0.00 |
| Net Income | -34.53M | -17.02M | -18.38M | -16.92M | -19.82M | -16.65M | -8.07M | -6.01M | -2.28M | -42.41K | -77.50K |
| Net Income Ratio | -137.10% | -89.88% | -444.78% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.04 | -0.02 | -0.02 | -0.05 | -0.19 | -0.18 | -0.09 | -0.08 | -0.05 | -0.04 | -0.23 |
| EPS Diluted | -0.04 | -0.02 | -0.02 | -0.05 | -0.19 | -0.18 | -0.09 | -0.08 | -0.05 | -0.04 | -0.23 |
| Weighted Avg Shares Out | 979.95M | 979.92M | 956.53M | 364.44M | 106.30M | 92.49M | 87.40M | 80.16M | 46.23M | 1.00M | 336.99K |
| Weighted Avg Shares Out (Dil) | 979.95M | 979.92M | 956.53M | 364.44M | 106.30M | 93.44M | 87.40M | 80.16M | 46.23M | 1.00M | 336.99K |
Zomedica to Present at Sidoti Virtual Investor Conference January 18-19
Zomedica: High Risk High Reward Play In Veterinary Supplies
How to Start Investing in Penny Stocks in 2023
Zomedica to Present at LD Micro Main Event XV Conference
Zomedica: Growing Veterinary Supply Company, Building Big Things On The Come
Zomedica to Present at H.C. Wainwright 24th Annual Global Investment Conference
2 Meme Stocks That Are Still Down 50% Since February 2021
Hot Meme Penny Stocks to Buy Now? 3 to Watch in August
Best Penny Stocks to Buy Right Now? 3 to Watch
ZOM Stock Pops 5% as Zomedica Acquires Revo Squared
Source: https://incomestatements.info
Category: Stock Reports
How has Zomedica’s diagnostic product revenue grown?
Zomedica (NYSE:ZOM) reported Q3 2024 financial results with revenue growing 10% to $7.0 million, maintaining a strong gross margin of 72.3%. The Diagnostics segment grew 38%, while the Therapeutic Device segment increased 9%.
What were Zomedica’s revenue and losses in the last 12 months?
In the last 12 months, Zomedica had revenue of $26.73 million and -$62.19 million in losses. Loss per share was -$0.06.